Skip to main content

People in the News: William Burns, Christoph Franz, Steven Averbuch, Michael Kolodziek

Premium

Roche said this week that William Burns will not stand for re-election to the board of directors. The company also said that it has proposed that Christoph Franz be elected as chairman of the board, and the remaining members of the board should be re-elected.

The remaining board members include Andre Hoffman; Andreas Oeri; Pius Baschera; John Irving Bell; Paul Bulcke; DeAnne Julius; Severin Schwan; Peter Voser; Arthur Levinson; and Beatrice Weder di Mauro.


The Personalized Medicine Coalition has appointed Steven Averbuch and Michael Kolodziek to seats on its board of directors.

Averbuch is VP of translational clinical diagnostic development and pharmacodiagnostics at Bristol-Myers Squibb and Kolodziek is national medical director of Oncology Solutions.

The two new members will join the board as the terms of Joanne Armstrong and Nancy Simonian expire at the end of 2013.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.